hero section gradient
7 handpicked stocks

Top Dividend Paying Stocks

These reliable companies have a proven track record of sharing profits with investors through regular dividend payments. Carefully selected by our professional analysts, these stocks offer the potential for both steady income and long-term growth.

Author avatar

Han Tan | Market Analyst

Published on May 3

Your Basket's Financial Footprint

Summary and key takeaways for the provided basket market capitalisation data.

Key Takeaways for Investors:
  • Large-cap dominance suggests generally lower volatility and more market-like returns, offering relative stability versus high-growth baskets.
  • Suitable as a core, long-term portfolio holding rather than a speculative, short-term growth position.
  • Expect steady income and gradual capital appreciation; not likely to deliver explosive short-term gains.
Total Market Cap
  • JNJ: $462.30B

  • KO: $306.39B

  • ABBV: $408.76B

  • Other

About This Group of Stocks

1

Our Expert Thinking

These stocks represent companies that consistently return a portion of their profits to shareholders through dividend payments. Many have increased their dividends for at least 10 consecutive years, demonstrating financial stability and a commitment to rewarding investors over time.

2

What You Need to Know

Dividend-paying stocks can provide regular income alongside potential stock price growth. Each company's management decides quarterly how much cash to distribute as dividends. These selections offer a balance between ongoing income and the possibility of long-term appreciation.

3

Why These Stocks

We've handpicked companies with impressive track records of not just paying dividends but increasing them year after year. These stocks represent established businesses with strong cash flows and management teams committed to sharing success with shareholders.

Why You'll Want to Watch These Stocks

💰

Get Paid While You Wait

Unlike growth-only stocks, these companies pay you regular dividends while you hold them. It's like earning interest on your investment even before you sell.

👑

Royal Treatment for Investors

These companies have increased their dividend payments for 10+ consecutive years, showing their commitment to treating shareholders like royalty through good times and bad.

🔄

Double Growth Potential

Enjoy the best of both worlds: regular income from dividends plus the potential for your investment to grow in value over time. It's two ways to build wealth with one investment.

Get the full story on this Basket. Read our detailed article on its risks and potential.

Read Full Insight

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

🚀

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Global Infrastructure Partners: UAE Exposure Risks

Global Infrastructure Partners: UAE Exposure Risks

The UAE's strategic push for economic diversification and smart city development is creating significant demand for advanced construction and infrastructure solutions. This basket provides exposure to a selection of US and EU-listed companies that supply essential materials, technology, and engineering services to the region's projects.

UAE Infrastructure Global Suppliers Breakdown

UAE Infrastructure Global Suppliers Breakdown

As the UAE continues its ambitious economic diversification, demand for world-class infrastructure creates opportunities for the companies that build it. This basket offers exposure to US and EU-listed industrial, materials, and technology firms that are integral to developing these large-scale projects.

Antiviral M&A Wave: Biotech Opportunities in 2025

Antiviral M&A Wave: Biotech Opportunities in 2025

Merck's $9.2 billion acquisition of Cidara Therapeutics strengthens its antiviral pipeline as a key patent nears expiry. This major deal signals a growing trend of pharmaceutical giants buying smaller biotechs, creating potential opportunities among companies with promising infectious disease therapies.

Frequently Asked Questions